Shots:

• FibroGen initiates the P-II study assessing the efficacy and safety of pamrevlumab vs SOC in hospitalized patients in a ratio (1:1) with acute COVID-19 across the US and is expected to enroll ~130 patients
• The focus of the study is to assess the effect of pamrevlumab on blood oxygenation in patients with COVID-19 with 1EPs as the proportion of hospitalized patients who have not received mechanical ventilation and ECMO and remain alive at day 28
• The company is expected to evaluate the longer-term efficacy and safety of pamrevlumab in patients who have recovered or are recovering from COVID-19 with evidence of interstitial lung disease in the second clinical study to be conducted in the US

Click here to read full press release/ article | Ref: PRNewswire | Image: Fibrogen